Fortress Biotech is a biopharmaceutical company focused on acquiring, developing and commercializing pharmaceutical and biotechnology products. Co.'s product candidates include: MB-107 (XSCID), an ex vivo lentiviral gene therapy for the treatment of X-linked severe combined immunodeficiency; Intravenous Tramadol, for the treatment of moderate to moderately severe post-operative pain; and CUTX-101, a copper histidinate injection for the treatment of Menkes disease. Co.'s other product candidates include: ConVax, CEVA-101, CEVA-D and CEVA-102, TAMID-001, AVTS-001, CNDO-109 and Methazalomide.

Preferred: FBIOP